Introduction {#Sec1}
============

Significant advances in the implementation of biomarkers in the clinical practice have been achieved in metastatic colorectal cancer (mCRC), even if only few of them (such as *RAS* and *BRAF* mutational status or microsatellite instability \[MSI\]) are endowed with clinical relevance. Furthermore, despite the advances achieved in understanding the molecular bases of resistance to EGFR targeting agents^[@CR1]--[@CR3]^, there is still a lack of biomarkers able to predict sensitivity/resistance to chemotherapy, which remains the cornerstone of treatment for most patients.

Cancer cells may gain the potential for uncontrolled growth by escaping functional cell-cycle checkpoints. By doing so, they simultaneously become vulnerable to both endogenous (*e*.*g*. oncogenic-driven replication stress) and exogenous (*e*.*g*. DNA-damaging agents) genotoxic insults^[@CR4]^. Tumors with homologous recombination deficiency are extremely sensitive to cross-linking agents such as platinum salts, or topoisomerase inhibitors. This mechanism has substantial implications in the clinical practice, specifically concerning the management of those tumors bearing deleterious *BRCA1-2* mutations (*e*.*g*. *BRCA*-mutated breast and ovarian cancer)^[@CR5],[@CR6]^.

*Ataxia-Telangiectasia Mutated* (*ATM*) is a gene member of the highly conserved PI3K-related kinases, on which cells rely for orchestrating the DNA damage response (DDR) for both DNA repair and cell-cycle checkpoint activation. Specifically, ATM is recruited upon DNA double strand breaks (DSBs) and is involved in DNA repair via both BRCA1-driven homologous recombination and non-homologous end-joining pathways, as well as in the G1/S cellular checkpoint activation through its major targets p53 and CHK2^[@CR7]^.

Germline and somatic mutations involving homologous recombination related genes, including *ATM*, are predicted to confer an enhanced platinum sensitivity^[@CR8]^. Specifically, ATM deficient tumors display a higher sensitivity to DNA DSB-inducing treatments^[@CR9]^ and loss of function mutations affecting the *ATM* gene could confer a vulnerability to DNA-damaging agents, especially in combination with p53 deficiency^[@CR10]--[@CR13]^. Because of the consistent prevalence of *ATM* mutations in CRC (7% in non-hypermutated cases)^[@CR14]^ and their potential crucial role as biomarker of chemosensitivity to platinum salts and topoisomerase inhibitors, *ATM* mutations would therefore characterize mCRC patients with a more favourable outcome, at least when eligible for combination chemotherapy. Moving from this background, we performed a translational study aimed at assessing the prognostic relevance of *ATM* mutational status in mCRC patients.

Materials and Methods {#Sec2}
=====================

Patients population {#Sec3}
-------------------

We retrieved pre-treatment tumor tissue blocks of initially unresectable mCRC patients treated at two Italian Institutions (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and Azienda Ospedaliero-Universitaria Pisana). Clinical, pathological and molecular characteristics at the time of diagnosis of metastatic disease were collected, including age, gender, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), primary tumor location (right- vs left-sided), primary tumor resection (yes vs no), time-to-metastases (synchronous vs metachronous), number of metastatic sites (1 vs \>1), *RAS* and *BRAF* mutational status, and MSI status. All included patients received at least one treatment line with doublet or triplet regimens with or without monoclonal antibodies according to standard clinical practice. The study was approved by the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Institutional Review Board (study ID: INT 117/15) and conducted according to the ethical principles for medical research involving human subjects adopted in the Declaration of Helsinki. All patients signed a written informed consent.

Next-generation sequencing analysis {#Sec4}
-----------------------------------

We centrally collected formalin-fixed paraffin-embedded archival tumor tissue blocks. Next-generation sequencing (NGS) data were obtained through the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies) with the Ion-Torrent™ Personal Genome Machine platform (Life Technologies), as previously described^[@CR15],[@CR16]^ and detailed in Supplementary Methods (see Supplementary Information). *ATM* and *TP53* mutational status was obtained, and *RAS* and *BRAF* mutational status was centrally confirmed. Heterogeneity score (HS) of *ATM* mutations was calculated as previously described by Normanno *et al*.^[@CR17]^. Briefly, the mutant allelic frequency was normalized for the neoplastic cell content, and the HS was calculated by multiplying by 2 the frequency of mutant alleles in neoplastic cells as somatic mutations usually involve only one allele.

Statistical analysis {#Sec5}
--------------------

Chi-square test or fisher exact test were used, as appropriate, to evaluate the association between *ATM* mutational status and the other relevant clinical and pathological patients' characteristics. Overall survival (OS) was calculated as the time from diagnosis of metastatic disease to the death from any cause. Since chemotherapy sensitivity putatively caused by *ATM* mutations may be boosted by the concomitant presence of *TP53* mutations^[@CR10]^ or primary tumor sidedness due to enrichment of mesenchymal and stem-like subtypes in right-sided tumors^[@CR18]^ we also evaluated the prognostic impact of combined *ATM* and *TP53* mutational status assessment as well as the prognostic impact of combined *ATM* mutational status and primary tumor location. The Kaplan-Meier method and the Cox proportional-hazards model were used for survival analyses. Hazard ratios (HRs) together with 95% confidence intervals (CI) were provided. Statistical significance threshold was set to a two-tailed 0.05 value. R software (version 3.5.0) and RStudio software (version 1.1.453) were used for Statistical analyses.

Results {#Sec6}
=======

Clinical, pathological and molecular features of *ATM* mutated mCRC {#Sec7}
-------------------------------------------------------------------

As detailed in the Consort diagram (Supplementary Fig. [S1](#MOESM1){ref-type="media"} in Supplementary Information), the final study population included a total of 227 patients, of whom 35 (15%) had *ATM* mutated tumors and 192 (85%) *ATM* wild-type tumors. *TP53* mutations were found in a total of 148 (65%) of samples, of whom 24 (69%) in the *ATM* mutated subgroup and 124 (65%) in *ATM* wild-type one (*P* = 0.65). Table [1](#Tab1){ref-type="table"} shows patients' demographics and disease characteristics, overall and according to *ATM* mutational status. Of note, *ATM* mutations were not significantly associated with specific clinical and molecular features. The exposure to specific agents approved for mCRC and the number of treatment lines received are summarized in Supplementary Table [S1](#MOESM1){ref-type="media"} (see Supplementary Information). Table [2](#Tab2){ref-type="table"} illustrates the specific mutations found in *ATM* gene and concomitant "trunk" mutations affecting *TP53*, *KRAS*, *NRAS*, *BRAF* and *APC*, with relative HS. The median HS for *ATM* mutations was 116 (IQR, 51--197).Table 1Patients' and disease characteristics, overall and according to *ATM* mutational status.CharacteristicsTotal\
(N = 227)\
N (%)*ATM* mut\
(N = 35)\
N (%)*ATM* wt\
(N = 192)\
N (%)*P\**Age (years)\<65\
≥65147 (65)\
80 (35)25 (71)\
10 (29)122 (64)\
70 (36)0.40GenderMale\
Female93 (41)\
134 (59)17 (49)\
18 (51)76 (40)\
116 (60)0.32ECOG PS0\
1--2\
NA197 (92)\
18 (8)\
1234 (97)\
1(3)\
0163 (91)\
17 (9)\
120.20Primary tumor locationLeft-sided\
Right-sided159 (70)\
68 (30)27 (77)\
8 (23)132 (69)\
60 (31)0.32Primary tumor resectionYes\
No192 (85)\
35 (15)31 (89)\
4 (11)161 (84)\
31 (16)0.48Synchronous metsNo\
Yes67 (30)\
160 (70)13 (37)\
22 (63)54 (28)\
138 (72)0.28Metastatic sites (N)1\>\
1135 (59)\
92 (41)24 (69)\
11 (31)111 (58)\
81 (42)0.23All-*RAS* statusWild-type\
Mutated127 (56)\
100 (44)20 (57)\
15 (43)107 (56)\
85 (44)0.88*BRAF* statusWild-type\
Mutated214 (94)\
13 (6)33 (94)\
2 (6)181 (94)\
11 (6)0.99MSI statusMSS\
MSI\
NA188 (94)\
13 (6)\
2626 (87)\
4 (13)\
5162 (95)\
9 (5)\
210.11\*Chi-square test or Fisher exact test, as appropriate.*Abbreviations*. ECOG PS: Eastern Cooperative Oncology Group Performance Status. MSI: microsatellite instability. MSS: microsatellite stability. Mut: mutated. Wt: wild-type.Table 2Specific mutations found in *ATM* gene with concomitant "trunk" mutations (affecting *TP53*, *KRAS*, *NRAS*, *BRAF* and *APC*) with relative heterogeneity score.IDMSI status*ATMTP53KRASNRASBRAFAPC*MutationHSMutationHSMutationHSMutationHSMutationHSMutationHS1MSIK610T60R248Q70G12V70------------E1464VfsTer8442NAE1325Stop94R175C180------------------------3MSSD2870H52------G12S114------------R1450Stop1064MSSR3047Stop88------G12D58------------R1450Stop465MSIR337C32------G13D36------------I1307K1566MSSP3050L254P278S173Q61H120------------------7MSIP604S132R196Stop194G12V140------------E1286Stop1988MSSR337C30I254S200G12V140------------R1450Stop649MSSA1309T136S215R192------------------S1346Stop7210MSSV410A230------------------------------11MSSR337H34---------------------I1311MfsTer1020012NAR2443Q184R273C290------------------E1353FfsTer2028413MSSR337C114------A146T212------------T1438HfsTer3510614MSSE1704D240------------------------E1379Stop71015MSSQ2729H128------A146T104------------T1556NfsTer37616MSSV410A200------------------------E1309DfsTer415817MSSR337H46R249G42G12V46------------------18MSSP604S194R273H306------------------Q12894Stop32019MSSR2691H52C238Y122------------------E1317Q15820MSSR337C50------G12V96------------H1349QfsTer416621MSSS333F40G266E760------------------------22MSSL1939V44R282W268------------------------23MSSV410A142I251S98------------------E1547Stop8624MSSV410A314Y205H207------------------------25MSSR337H108R175H196G13D190------------------26MSSS333F290R273C140------------------------27MSSS1691R204R175H113------------------------28MSSsplice site 184_185 + K1992T212 + 102V73fs\*5090------------V600E350------29MSIF1928fs\*9206R27H + R17H340------------V600E468------30MSSF858L300V274F66------------------------31MSSR337H20------A146T140------------------32MSSR2912G116R2912G400------G12S120------------33MSSG2695V46G245S60------------------R1450Stop5034MSSV410A132R273C108G12V---------------R1450Stop6235MSSF858L146R282W202------------------Q1291Stop84*Abbreviations*. HS: heterogeneity score. MSI: microsatellite instability. MSS: microsatellite stability.

Prognostic role of ATM mutations in mCRC patients {#Sec8}
-------------------------------------------------

At a median follow-up of 56.6 months (95% CI, 46.3--62.1), patients with *ATM* mutated tumors showed a significantly longer median OS than patients with *ATM* wild-type tumors (64.9 versus 34.8 months; HR, 0.50; 95% CI, 0.29--0.85; *P* = 0.01) (Fig. [1](#Fig1){ref-type="fig"}). In the multivariable model (Table [3](#Tab3){ref-type="table"}), including other covariates significantly associated with OS, the presence of *ATM* mutations confirmed its association with improved OS (HR, 0.57; 95% CI, 0.33--0.98; *P* = 0.04), along with left-sided primary tumor location (*P* = 0.005), primary tumor resection (*P* = 0.003), metachronous metastases (*P* = 0.005) and the presence of a single site of metastasis (*P* = 0.03).Figure 1Kaplan-Meier curves for overall survival according to *ATM* mutational status. Red line indicates patients with *ATM* mutated tumors, blue line indicates patients with *ATM* wild-type tumors.Table 3Univariate and multivariate analyses for overall survival.CharacteristicsUnivariate analysesMultivariable modelHR (95% CI)*P*HR (95% CI)*P*Age (years)≥65 vs \<651.60 (1.10--2.20)**0.009**---0.25GenderFemale vs Male---0.24------ECOG PS1--2 vs 0---0.15------Primary tumor locationRight vs Left2.00 (1.40--2.80)**\<0.001**1.70 (1.17--2.46)**0.005**Primary tumor resectionNo vs Yes1.90 (1.20--2.90)**0.005**1.62 (1.04--2.54)**0.03**Synchronous metsYes vs No1.80 (1.20--2.60)**0.003**1.76 (1.19--2.61)**0.005**Metastatic sites (N)\>1 vs 11.70 (1.20--2.40)**0.002**1.47 (1.03--2.08)**0.03**All-*RAS* statusMut vs wt---0.06------*BRAF* statusMut vs wt2.10 (1.10--4.00)**0.03**---0.09MSI statusMSI vs MSS---0.16------*ATM* statusMut vs wt0.50 (0.29--0.85)**0.01**0.57 (0.33--0.98)**0.04***Abbreviations*. ECOG PS: Eastern Cooperative Oncology Group Performance Status. Mets: metastases. MSI: microsatellite instability. MSS: microsatellite stable. Mut: mutated. Wt: wild-type.

Among patients with *ATM* mutated tumors, an HS ≥ 100 for *ATM* mutations was associated with a longer median OS compared with an HS \< 100 (70.1 versus 38.5 months; HR, 0.28; 95% CI 0.09--0.85; *P* = 0.02) (Fig. [2](#Fig2){ref-type="fig"}). Therefore, when using patients with wild-type *ATM* as reference, the HR for patients with *ATM* mutated tumors and HS \< 100 was 0.91 (95% CI, 0.44--1.86; *P* = 0.79), whereas it relevantly decreased for patients with *ATM* mutated tumors and HS ≥ 100 (HR, 0.57; 95% CI, 0.39--0.84; *P* = 0.004).Figure 2Kaplan-Meier curves for overall survival according to *ATM* mutational status and *ATM* mutational heterogeneity score. Red line indicates patients with *ATM* mutated tumors and *ATM* HS ≥ 100, blue line indicates patients with *ATM* mutated tumors and *ATM* HS \< 100, black line indicated patients with *ATM* wild-type tumors. *Abbreviations*: HS: heterogeneity score.

Of note, no prognostic significance was observed for *TP53* mutational status (*P* = 0.79), and the prognostic impact of *ATM* mutations was completely independent from the concomitant presence of *TP53* mutations (Supplementary Fig. [S2](#MOESM1){ref-type="media"} in Supplementary Information) or primary tumor sidedness (Supplementary Fig. [S3](#MOESM1){ref-type="media"} in Supplementary Information).

Finally, since we performed a massively parallel sequencing of multiple cancer-related genes, we assessed the prognostic value of the top mutated genes (i.e. those found mutated in at least 5% of samples: *ATM*, *KRAS*, *BRAF*, *NRAS*, *APC*, *PIK3CA*, *SMAD4*, *FBXW7* and *MET*) and applied the Benjamini--Hochberg procedure in order to decrease the false discovery rate, demonstrating that the *P*-value for *ATM* mutational status remained significant (*P* = 0.04) (Supplementary Table [S2](#MOESM1){ref-type="media"} in Supplementary Information).

Discussion {#Sec9}
==========

Given the crucial role of ATM activity in orchestrating the DDR, relevant phenotypic spillover is awaited upon its loss. However, as a result of both biological complexity of the DDR network and heterogeneity across different studies, no conclusive clinical data are available on ATM prognostic and/or predictive impact.

In early stage CRC, low ATM expression has been previously associated with worse outcomes. In a series of 330 early CRCs, the presence of ATM expression detected by immunohistochemistry (IHC) was associated with disease-free survival and OS benefit when considering patients who underwent adjuvant treatments (N = 33)^[@CR19]^. Similar results have been confirmed by a subgroup analysis of the VICTOR trial, which included stage II/III CRC patients undergoing adjuvant fluoropyrimidine-based chemotherapy^[@CR20]^. Regarding the metastatic setting, a recent monocentric study showed that ATM deficiency (as primarily assessed by IHC) may be associated with improved OS following oxaliplatin-based first-line treatment, but not irinotecan-based one^[@CR21]^. Discrepancy in available evidences might be related to the different prognostic role of ATM loss of function according to disease stage, similarly to what reported for MSI^[@CR22]^, and the confounding effects derived from the heterogeneity of available regimens and treatment sequences used for metastatic disease.

This is the larger available study assessing the role of *ATM* mutations as prognostic biomarker in mCRC. Here, the presence of *ATM* mutations was independently associated with improved OS (adjusted HR, 0.57; 95% CI, 0.33--0.98; *P* = 0.04). These results suggest that *ATM* mutations might identify a biologically distinct disease with a survival advantage in the metastatic setting linked, at least in part, to an increased chemosensitivity. Intriguingly, patients with *ATM* mutations and an HS ≥ 100, showed the best outcomes in terms of OS. As previously described by Normanno *et al*.^[@CR17]^, HS virtually corresponds to the fraction of neoplastic cells bearing a specific mutation. Specifically, an HS \> 100 might reflect the loss of the wild-type allele. HS might help identifying tumors with a "functional knock-out" of ATM that lose their ability of properly coping with DNA damage. Therefore *ATM* HS should be taken into account by future studies and potentially correlated with functional data.

From a preclinical point of view, p53 is one of the most characterized ATM targets, required for G1/S cell arrest and apoptosis. Conceptually, drugs inducing high amount of DNA damage in S phase in cells with both DNA repair and G1/S--G2/M checkpoint deficiency (such as those bearing both *ATM* and *TP53* mutations) are likely to induce a mitotic catastrophe-mediated cell death^[@CR23]^. However, we did not find any clinically relevant interaction between *ATM* and *TP53* mutational status in impacting on OS (Supplementary Fig. [S2](#MOESM1){ref-type="media"} in Supplementary Information). It must be pointed out that, even if ATM or CHK2 suppression preferentially sensitizes p53 deficient tumors to genotoxic drugs, a chemosensitivity status driven by ATM deficiency might occur independently from *TP53*^[@CR24]^.

In addition, an enrichment of *ATM* mutations is expected in mCRC patients with right-sided tumors^[@CR18]^, MSI-high^[@CR14]^ or CMS1 ones^[@CR25]^. In our study, the prognostic impact of *ATM* mutational status was independent from primary tumor location status (Table [3](#Tab3){ref-type="table"} and Supplementary Fig. [S3](#MOESM1){ref-type="media"} in Supplementary Information), even if the low number of patients with *ATM* mutations and right-sided mCRC highlights the need of larger datasets to specifically assess the impact of DDR alterations according to primary tumor location or disease subtypes.

Our study has some limitations. For instance, despite the strong rationale making *ATM* mutational status a candidate biomarker of response to oxaliplatin and/or irinotecan^[@CR26]--[@CR29]^, we have not considered response rate or progression-free survival because of the heterogeneity of treatment regimens as per standard practice (fluoropyrimidine monotherapy, doublet or triplet chemotherapy regimens associated or not with anti-VEGF or anti-EGFR). Of course, an integrated assessment of both protein expression and mutational status would be necessary for identifying all tumors with clinically relevant *ATM* loss of function. In fact, other mechanisms might account for ATM reduced activity, such as low expression due to promoter methylation^[@CR30]^. Indeed, a comprehensive assessment of the DDR network on a proteomic scale is expected to reach the best accuracy for predicting chemosensitivity.

Beyond being a sole biomarker of chemosensitivity, *ATM* mutations might predict response to DDR-targeting agents paralleling recent achievements in other clinical settings, such as castration-resistant prostate cancer (CRPC). Indeed, in the TOPARP-A phase II trial CRPC patients bearing alterations in homologous recombination repair genes displayed a high response rate to the PARP inhibitor olaparib (including 4 out of 5 patients with tumors bearing *ATM* mutations)^[@CR31]^. Similar therapeutic approach would be backed by a strong preclinical rationale also in CRC^[@CR32]^. The reader is referred to Choi *et al*.^[@CR33]^ for reviewing potential synthetic lethality strategies (*e*.*g* PARP1 or ATR inhibitors) in ATM deficient tumors.

In conclusion, our study suggests that *ATM* mutations with high HS might characterize a subset of mCRC at better prognosis. From this background, further investigations are needed to cover crucial unresolved issues such as the assessment of functional relevance of specific *ATM* mutations and their predictive role upon specific DNA damaging and/or DDR-targeting agents. Indeed, synthetic lethality strategies might be preferentially used in ATM deficient tumors, while ATM proficient tumors might be sensitized to conventional therapies by ATM inhibitors^[@CR34]^. Thus, *ATM* mutational status could enter the clinical decision-taking process in parallel with the development of specific targeted strategies.
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